ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 04 Jan 2022
Last Updated on 04 Jan 2022
A- A+
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended:
  • Ranibizumab 1.65 mg/0.165 ml pre-filled syringe and 2.3 mg/0.23 ml solution for injection as an alternative to intravitreal bevacizumab for treating adults with visual impairment due to:
    • neovascular (wet) age-related macular degeneration;
    • diabetic macular oedema; and
    • macular oedema secondary to central or branch retinal vein occlusion
in view of an acceptable price proposal from the manufacturer.

Subsidy status

Ranibizumab is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indications.

Ranibizumab for treating age-related macular degeneration, diabetic macular oedema and retinal vein occlusion (4 Jan 2022)